Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Darunavir (Prezista®) for the treatment of HIV-1 infected, treatment-naïve adults in combination with other antiretroviral medicinal products. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2009. 2009 Authors' conclusions Darunavir (Prezista®) co-administered with low dose ritonavir is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus (HIV)-1 infection in treatment naive patients.
AWMSG is of the opinion that darunavir (Prezista®) is not suitable for shared care within NHS Wales. Indexing Status Subject indexing assigned by CRD MeSH Anti-HIV Agents; HIV-1; Humans; Sulfonamides Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000396 Date abstract record published 08/08/2012 |
